Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

magazine

New drug approvals ease fears of a regulatory slowdown

The amount of FDA-approved drugs has already beaten last year’s total
Thursday 24 Aug 2017 Author: Lisa-Marie Janes
Story In Numbers

Drug approvals by the US Food and Drug Administration (FDA) are making a strong comeback after a lull in 2016. Market intelligence firm Evaluate says 28 new drugs were given the green light in the year to 19 July 2017, which has already exceeded the 26 approved in 2016.

Evaluate believes the FDA is on track to approve up to 43 new drugs this year and hopes this will address fears of a regulatory or innovative slowdown.

‹ Previous2017-08-24Next ›


24 Aug 2017

Download PDF

Page flip version

Important information:

These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.

Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.

Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.

The Shares team
Disclaimer

Issue contents

Big News

Editor's View

Funds

Great Ideas

Great Ideas Update

Investment Trusts

Larger Companies

Main Feature

Money Matters

Smaller Companies

Story In Numbers

Talking Point

Under The Bonnet

Week Ahead

Magazine archive


31 Jul 2025
24 Jul 2025
17 Jul 2025

10 Jul 2025
3 Jul 2025
26 Jun 2025

19 Jun 2025
12 Jun 2025
5 Jun 2025